Keratinocyte growth factor in focus: A comprehensive review from structural and functional aspects to therapeutic applications of palifermin.
Palifermin (Kepivance™) is the first therapeutic approved by the Food and Drug Administration for preventing and managing the oral mucositis provoked by myelotoxic and mucotoxic therapies. Palifermin is a recombinant protein generated from human keratinocyte growth factor (KGF) and imitates the function of endogenous KGF. KGF is an epithelial mitogen involved in various biological processes which belongs to the FGF family. KGF possesses a high level of receptor specificity and plays an important role in tissue repair and maintaining of the mucosal barrier integrity. Based on these unique features, palifermin was developed to enhance the growth of damaged epithelial tissues. Administration of palifermin has shown success in the reduction of toxicities of chemotherapy and radiotherapy, and improvement of the patient's quality of life. Notwithstanding all merits, the clinical application of palifermin is limited owing to its instability and production challenges. Hence, a growing number of ongoing researches are designed to deal with these problems and enhance the physicochemical and pharmaceutical properties of palifermin. In the current review, we discuss KGF structure and function, potential therapeutic applications of palifermin, as well as the latest progress in the production of recombinant human KGF and its challenges ahead.
['Sadeghi|Solmaz|S|', 'Kalhor|Hourieh|H|', 'Panahi|Mohammad|M|', 'Abolhasani|Hoda|H|', 'Rahimi|Bahareh|B|', 'Kalhor|Reyhaneh|R|', 'Mehrabi|Amirmehdi|A|', 'Vahdatinia|Mahsa|M|', 'Rahimi|Hamzeh|H|']
Oral mucositis KGF Fibroblast growth factor Therapeutic proteins cancer therapy